San Francisco-based Meissa Vaccines has announced it is intiating pre-clinical studies of its live attenuated vaccine (LAV) against SARS-CoV-2, the virus which causes Covid-19.

The vaccine candidate, MV-014-210, is a intranasal, adjuvant free vaccine, which was build on Meissa’s respiratory syncytial virus (RSV) vaccine platform.

Meissa also announced it has completed its pre-investigational new drug application with the US Food and Drug Administration.

The company’s CEO and co-founder Martin Moore noted: “The Covid-19 vaccine pipeline is dominated by non-replicating vaccines, while live attenuated vaccines are known to induce long-lasting immunity after a single adjuvant-free dose, presenting an economical and effective solution to this global pandemic.

“A single dose of MV-014-210 may be sufficient to generate immunity against SARS-CoV-2. Furthermore, building our Covid-19 vaccine candidate on our RSV vaccine platform provides safety advantages compared to a live attenuated coronavirus approach.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.